NICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give patients the chance to receive a potentially curative bone marrow transplant.
A combination of Novartis’ 'next generation' CAR-T drug CTL119 with Janssen and AbbVie's Imbruvica has cleared all signs of chronic lymphocytic leukaemia from eight out of nine patients in
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.